Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2

Technology appraisal guidance
Reference number: TA257
Published: 27 June 2012

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): responses to comments on the economic model by the Assessment Group

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): responses to comments on the economic model by the Assessment Group

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): responses to comments on the economic model by the Assessment Group
01 July 2011
(100.34 Kb 29 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 30 June 2011